REVENUES

3 Months Ended

Mar. 31, 2021

REVENUES

REVENUES

NOTE 4 – REVENUES

The following table summarizes the Company’s disaggregation of revenues:

	Three Months Ended March 31,
(U.S. dollars in thousands)	2021		2020
Pfizer	$	4,511	$	2,016
Brazil	$	—	$	3,015
Total revenues from selling goods	$	4,511	$	5,031
Revenues from license and R&D services	$	6,809	$	16,615

During the three months ended March 31, 2020, the Company recorded revenue in the amount of $6.7 million following a change in estimate of the total costs expected to be incurred in connection with the Chiesi Agreements.